Trapping Poly(ADP-Ribose) Polymerase

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Journal of Pharmacology and Experimental Therapeutics

• Publication date

  2015-06-01

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1124/jpet.114.222448PMID 25758918
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Corrigendum: The zinc-finger domains of PARP1 cooperate to recognize DNA strand breaks

  2015cited by this paper
• Poly(ADP-Ribose) Polymerase 1 (PARP1) Overexpression in Human Breast Cancer Stem Cells and Resistance to Olaparib

  2014cited by this paper
• Inhibition of poly(ADP-ribosyl)ation in cancer: old and new paradigms revisited.

  2014cited by this paper
• Histone deacetylase inhibitor treatment induces ‘BRCAness’ and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cells

  2014cited by this paper
• Structural basis for the inhibition of poly(ADP-ribose) polymerases 1 and 2 by BMN 673, a potent inhibitor derived from dihydropyridophthalazinone

  2014influential reference
• Targeting PARP-1 allosteric regulation offers therapeutic potential against cancer.

  2014cited by this paper
• Discovery and Structure–Activity Relationship of Novel 2,3-Dihydrobenzofuran-7-carboxamide and 2,3-Dihydrobenzofuran-3(2H)-one-7-carboxamide Derivatives as Poly(ADP-ribose)polymerase-1 Inhibitors

  2014influential reference
• 246 PARP inhibitors trap PARP1 onto damaged DNA via catalytic inhibition and not by an allosteric mechanism

  2014cited by this paper
• Base Excision Repair Defects Invoke Hypersensitivity to PARP Inhibition

  2014cited by this paper
• 242 BMN 673 as single agent and in combination with temozolomide or PI3K pathway inhibitors in small cell lung cancer and gastric cancer models

  2014cited by this paper
• Abstract 2734: Veliparib (ABT-888) potentiates the cytotoxic activity of DNA alkylating agents by trapping PARP onto damaged chromatin

  2014cited by this paper
• Conformational Activation of Poly(ADP-ribose) Polymerase-1 upon DNA Binding Revealed by Small-Angle X-ray Scattering

  2014cited by this paper
• Rationale for Poly(ADP-ribose) Polymerase (PARP) Inhibitors in Combination Therapy with Camptothecins or Temozolomide Based on PARP Trapping versus Catalytic Inhibition

  2014cited by this paper
• Synergistic Activity of PARP Inhibition by Talazoparib (BMN 673) with Temozolomide in Pediatric Cancer Models in the Pediatric Preclinical Testing Program

  2014cited by this paper
• PARP1–TDP1 coupling for the repair of topoisomerase I–induced DNA damage

  2014influential reference
• Molecular Pathways Molecular Pathways : How Can BRCA-Mutated Tumors Become Resistant to PARP Inhibitors ?

  2014cited by this paper
• Interactions Between Ataxia Telangiectasia Mutated Kinase Inhibition, Poly(ADP-ribose) Polymerase-1 Inhibition and BRCA1 Status in Breast Cancer Cells

  2014cited by this paper
• Investigating the allosteric reverse signalling of PARP inhibitors with microsecond molecular dynamic simulations and fluorescence anisotropy.

  2014influential reference
• Targeting the DNA repair pathway in Ewing sarcoma.

  2014cited by this paper
• PARP inhibitors in cancer therapy: an update

  2013cited by this paper
• A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation

  2013cited by this paper
• Structural Implications for Selective Targeting of PARPs

  2013influential reference
• PARP-1 mechanism for coupling DNA damage detection to poly(ADP-ribose) synthesis.

  2013influential reference
• BMN 673, a Novel and Highly Potent PARP1/2 Inhibitor for the Treatment of Human Cancers with DNA Repair Deficiency

  2013influential reference
• A Genetic Screen Using the PiggyBac Transposon in Haploid Cells Identifies Parp1 as a Mediator of Olaparib Toxicity

  2013influential reference
• Discovery of novel benzo[b][1,4]oxazin-3(4H)-ones as poly(ADP-ribose)polymerase inhibitors.

  2013cited by this paper
• Design, synthesis, and biological evaluation of a series of benzo[de][1,7]naphthyridin-7(8H)-ones bearing a functionalized longer chain appendage as novel PARP1 inhibitors.

  2013cited by this paper
• Strategic Combination of DNA-Damaging Agent and PARP Inhibitor Results in Enhanced Cytotoxicity

  2013cited by this paper
• Cisplatin resistance associated with PARP hyperactivation.

  2013cited by this paper
• PARP and CHK inhibitors interact to cause DNA damage and cell death in mammary carcinoma cells

  2013cited by this paper
• Therapeutic applications of PARP inhibitors: anticancer therapy and beyond.

  2013influential reference
• Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib

  2013cited by this paper
• Drugging topoisomerases: lessons and challenges.

  2013influential reference
• PARP inhibitors: polypharmacology versus selective inhibition

  2013influential reference
• PARP inhibitor with selectivity toward ADP-ribosyltransferase ARTD3/PARP3.

  2013cited by this paper
• Proteomic Markers of DNA Repair and PI3K Pathway Activation Predict Response to the PARP Inhibitor BMN 673 in Small Cell Lung Cancer

  2013cited by this paper
• The DNA damage response and cancer therapy

  2012cited by this paper
• DNA repair dysregulation from cancer driver to therapeutic target

  2012cited by this paper
• Developing rational drug combination strategies for PARP inhibitors.

  2012cited by this paper
• DNA Damage and Cellular Stress Responses Increased PARP-1 Association with DNA in Alkylation Damaged , PARP-Inhibited Mouse Fibroblasts

  2012influential reference
• Development and Validation of an Immunoassay for Quantification of Topoisomerase I in Solid Tumor Tissues

  2012cited by this paper
• Enhancing CHK1 inhibitor lethality in glioblastoma

  2012cited by this paper
• Family-wide chemical profiling and structural analysis of PARP and tankyrase inhibitors

  2012cited by this paper
• Temozolomide: mechanisms of action, repair and resistance.

  2012cited by this paper
• Interfacial inhibitors: targeting macromolecular complexes

  2012cited by this paper
• Structural basis of selective inhibition of human tankyrases.

  2012cited by this paper
• The structure of DNA-bound human topoisomerase II alpha: conformational mechanisms for coordinating inter-subunit interactions with DNA cleavage.

  2012cited by this paper
• Towards a structural understanding of PARP1 activation and related signalling ADP-ribosyl-transferases.

  2012influential reference
• Synthetic Lethal Interactions between EGFR and PARP Inhibition in Human Triple Negative Breast Cancer Cells

  2012cited by this paper
• Structural Basis for DNA Damage–Dependent Poly(ADP-ribosyl)ation by Human PARP-1

  2012influential reference
• The zinc-finger domains of PARP1 cooperate to recognize DNA strand breaks

  2012cited by this paper
• On PAR with PARP: cellular stress signaling through poly(ADP-ribose) and PARP-1.

  2012cited by this paper
• Predicting Enhanced Cell Killing through PARP Inhibition

  2012cited by this paper
• Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors.

  2012influential reference
• Crystal Structures of Poly(ADP-ribose) Polymerase-1 (PARP-1) Zinc Fingers Bound to DNA

  2011cited by this paper
• PARP-1 and PARP-2: New players in tumour development.

  2011cited by this paper
• Biomarkers of PARP inhibitor sensitivity

  2011cited by this paper
• Exploiting the homologous recombination DNA repair network for targeted cancer therapy.

  2011cited by this paper
• The underlying mechanism for the PARP and BRCA synthetic lethality: Clearing up the misunderstandings

  2011cited by this paper
• Structural studies of the PARP-1 BRCT domain

  2011cited by this paper
• COMPROMISED CDK1 ACTIVITY SENSITIZES BRCA-PROFICIENT CANCERS TO PARP INHIBITION

  2011cited by this paper
• Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies.

  2011cited by this paper
• Enhanced Killing of Cancer Cells by Poly(ADP-ribose) Polymerase Inhibitors and Topoisomerase I Inhibitors Reflects Poisoning of Both Enzymes*

  2011cited by this paper
• Discovery and characterization of novel potent PARP-1 inhibitors endowed with neuroprotective properties: From TIQ-A to HYDAMTIQ

  2011cited by this paper
• Poly(ADP-ribose) polymerase and XPF–ERCC1 participate in distinct pathways for the repair of topoisomerase I-induced DNA damage in mammalian cells

  2011cited by this paper
• Poly (ADP-ribose) polymerase (PARP) is not involved in base excision repair but PARP inhibition traps a single-strand intermediate

  2010cited by this paper
• PARP inhibition: PARP1 and beyond

  2010influential reference
• Evolution of poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors. From concept to clinic.

  2010influential reference
• Optimization of phenyl-substituted benzimidazole carboxamide poly(ADP-ribose) polymerase inhibitors: identification of (S)-2-(2-fluoro-4-(pyrrolidin-2-yl)phenyl)-1H-benzimidazole-4-carboxamide (A-966492), a highly potent and efficacious inhibitor.

  2010influential reference
• Discovery and SAR of substituted 3-oxoisoindoline-4-carboxamides as potent inhibitors of poly(ADP-ribose) polymerase (PARP) for the treatment of cancer.

  2010cited by this paper
• DNA topoisomerases and their poisoning by anticancer and antibacterial drugs.

  2010influential reference
• The PARP side of the nucleus: molecular actions, physiological outcomes, and clinical targets.

  2010cited by this paper
• Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval.

  2010cited by this paper
• Molecular and Cellular Pathobiology Cancer Research Poly ( ADP-Ribose ) Polymerase Is Hyperactivated in Homologous Recombination – Defective Cells

  2010cited by this paper
• Acquired Resistance to Combination Treatment with Temozolomide and ABT-888 Is Mediated by Both Base Excision Repair and Homologous Recombination DNA Repair Pathways

  2009influential reference
• Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy.

  2009cited by this paper
• Synthesis and SAR of novel tricyclic quinoxalinone inhibitors of poly(ADP-ribose)polymerase-1 (PARP-1).

  2009cited by this paper
• Topoisomerase I levels in the NCI-60 cancer cell line panel determined by validated ELISA and microarray analysis and correlation with indenoisoquinoline sensitivity

  2009cited by this paper
• Discovery of the Poly(ADP-ribose) polymerase (PARP) inhibitor 2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide (ABT-888) for the treatment of cancer.

  2009influential reference
• Topoisomerase levels determine chemotherapy response in vitro and in vivo

  2008influential reference
• A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair.

  2008cited by this paper
• Targeting DNA.

  2008cited by this paper
• A Third Zinc-binding Domain of Human Poly(ADP-ribose) Polymerase-1 Coordinates DNA-dependent Enzyme Activation*

  2008cited by this paper
• Mechanisms of Chemoresistance to Alkylating Agents in Malignant Glioma

  2008influential reference
• PARP1-dependent Kinetics of Recruitment of MRE11 and NBS1 Proteins to Multiple DNA Damage Sites*

  2008cited by this paper
• Nonclassic functions of human topoisomerase I: genome-wide and pharmacologic analyses.

  2007influential reference
• Metformin-associated lactic acidosis in Sweden 1977–1991

  2006cited by this paper
• Inhibition of poly (ADP-ribose) polymerase activates ATM which is required for subsequent homologous recombination repair

  2006cited by this paper
• Mechanisms of cellular resistance to camptothecins.

  2006cited by this paper
• Repair of topoisomerase I-mediated DNA damage.

  2006cited by this paper
• Poly(ADP-ribose): novel functions for an old molecule

  2006cited by this paper
• Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition.

  2006cited by this paper
• Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

  2005cited by this paper
• Poly(ADP-ribose) Polymerase Activity Prevents Signaling Pathways for Cell Cycle Arrest after DNA Methylating Agent Exposure*

  2005influential reference
• Synthesis and mechanism of action studies of a series of norindenoisoquinoline topoisomerase I poisons reveal an inhibitor with a flipped orientation in the ternary DNA-enzyme-inhibitor complex as determined by X-ray crystallographic analysis.

  2005cited by this paper
• Discovery of quinazolinone and quinoxaline derivatives as potent and selective poly(ADP‐ribose) polymerase‐1/2 inhibitors

  2005cited by this paper
• Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

  2005cited by this paper
• Inhibitor‐induced structural change of the active site of human poly(ADP‐ribose) polymerase

  2004influential reference
• Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361.

  2004cited by this paper
• Involvement of Poly(ADP-ribose) Polymerase-1 and XRCC1/DNA Ligase III in an Alternative Route for DNA Double-strand Breaks Rejoining*

  2004cited by this paper

• Distinct p21 dynamics drive alternative routes to whole-genome duplication through a common CDK4/6-dependent polyploid G0 state

  2026cites this paper
• Metformin Sensitizes PTEN-deficient Prostate Cancer to PARP Inhibitors by Rebuilding NADP+ Homeostasis

  2026cites this paper
• The evolving landscape of antibody-drug conjugates (ADCs) for treatment of prostate cancer

  2025cites this paper
• PARPs and PARP inhibitors: molecular mechanisms and clinical applications

  2025cites this paper
• Talazoparib Monotherapy in Metastatic Castration-resistant Prostate Cancer with DNA Damage Response Alterations-Genomic Features Associated with Response to Therapy.

  2025cites this paper
• Poly (ADP-ribose) polymerase (PARP) inhibitors approved for the treatment of cancer.

  2025cites this paper
• PARP1 in Melanoma: Mechanistic Insights and Implications for Basic and Clinical Research.

  2025cites this paper
• The Synergistic Effect of PARP Inhibitors and Irinotecan in Small Cell Lung Cancer Cells

  2025cites this paper
• Targeting PARP1: A Promising Approach for Next-Generation Poly (ADP-ribose) Polymerase Inhibitors

  2025cites this paper
• JPI-547, a Dual Inhibitor of PARP/Tankyrase, Shows Antitumor Activity Against Pancreatic Cancers with Homologous Recombination Repair Deficiency or Wnt-Addiction

  2025cites this paper
• All roads lead to mitosis: a common requirement for DNA replication stress-dependent and -independent killing of BRCA-deficient cells.

  2025cites this paper
• Discovery of novel thiosemicarbazone dimers as effective inhibitors of poly(ADP-ribose) polymerase-1 (PARP-1) for use in cancer therapy.

  2025cites this paper
• Recent Progress in Poly(ADP–Ribose) Polymerase‐1 Inhibitors for Application in Cancer

  2025cites this paper
• Image Correlation Spectroscopy is a Robust Tool to Quantify Cellular DNA Damage Response

  2025cites this paper
• Research Progress on the Combination of PARP Inhibitors (PARPi) and Immune Checkpoint Inhibitors (ICIs)

  2025cites this paper
• Combining Homologous Recombination-Deficient Testing and Functional RAD51 Analysis Enhances the Prediction of Poly(ADP-Ribose) Polymerase Inhibitor Sensitivity

  2024cites this paper
• A synergistic two-drug therapy specifically targets a DNA repair dysregulation that occurs in p53-deficient colorectal and pancreatic cancers

  2024cites this paper
• Unravelling the molecular basis of PARP inhibitor resistance in prostate cancer with homologous recombination repair deficiency.

  2024cites this paper
• PARP inhibitors in gliomas: Mechanisms of action, current trends and future perspectives.

  2024cites this paper
• Olaparib-induced myelodysplasia – A case report

  2024cites this paper
• Regulation of PARP1/2 and the tankyrases: emerging parallels.

  2024cites this paper
• Therapeutic targeting of PARP with immunotherapy in acute myeloid leukemia

  2024cites this paper
• A Theoretical Study of the Interaction of PARP-1 with Natural and Synthetic Inhibitors: Advances in the Therapy of Triple-Negative Breast Cancer

  2024cites this paper
• Novel inhibitors of PARP1 and PARP14: design, synthesis, and potentiation of cisplatin efficacy in cancer.

  2024cites this paper
• Synergistic antitumor effect of liposomal-based formulations of olaparib and topotecan in primary epithelial ovarian cancer cells

  2024cites this paper
• Optimizing and Validating Systemic DNA Damage Response Profiling to Predict Neoadjuvant Chemoradiation Response in Rectal Cancer

  2024cites this paper
• Targeting BRCA and PALB2 in Pancreatic Cancer

  2024cites this paper
• Synthetically accessible de novo design using reaction vectors: Application to PARP1 inhibitors

  2024cites this paper
• The discovery of a potent PARP1 inhibitor Senaparib.

  2024cites this paper
• Emerging strategies to overcome PARP inhibitors' resistance in ovarian cancer.

  2024cites this paper
• Enhancing Effects of Olaparib by Alpha- and Beta-Emitting Radionuclides, X-Rays, and Ultraviolet A Light in Combination with Ortho-IodoHoechst in a Prostate Cancer Cell Model

  2024cites this paper
• DNA damage response inhibitors in cancer therapy: lessons from the past, current status and future implications

  2024cites this paper
• Olaparib monotherapy or in combination with abiraterone for treating mutated metastatic castration-resistant prostate cancer: alone or stronger together?

  2024cites this paper
• A new wave of innovations within the DNA damage response

  2023cites this paper
• Hypoxia-activated prodrugs of phenolic olaparib analogues for tumour-selective chemosensitisation.

  2023cites this paper
• Identification of [1,2,4]Triazolo[4,3-a]pyrazine PARP1 inhibitors with overcome acquired resistance activities.

  2023cites this paper
• Identification of indole-based natural compounds as inhibitors of PARP-1 against triple-negative breast cancer: a computational study

  2023cites this paper
• Efficacy and safety of PARP inhibitors in metastatic castration-resistant prostate cancer: A systematic review and meta-analysis of clinical trials.

  2023cites this paper
• Advancements and Obstacles of PARP Inhibitors in Gastric Cancer

  2023cites this paper
• PARP inhibitors: A review of the pharmacology, pharmacokinetics, and pharmacogenetics.

  2023cites this paper
• PARP1 associates with R-loops to promote their resolution and genome stability

  2023cites this paper
• Kidney Function in Patients with Ovarian Cancer Treated with Poly (ADP-ribose) polymerase (PARP) Inhibitors.

  2023cites this paper
• An 19F NMR fragment-based approach for the discovery and development of BRCA2-RAD51 inhibitors to pursuit synthetic lethality in combination with PARP inhibition in pancreatic cancer.

  2023cites this paper
• Synthesis of Veliparib Prodrugs and Determination of Drug-Release-Dependent PARP-1 Inhibition

  2023cites this paper
• Polyadenosine diphosphate-ribose polymerase inhibitors: advances, implications, and challenges in tumor radiotherapy sensitization

  2023cites this paper
• Enhancing the anti-tumor response by combining DNA damage repair inhibitors in the treatment of solid tumors.

  2023cites this paper
• WRN inhibition leads to its chromatin-associated degradation via the PIAS4-RNF4-p97/VCP axis

  2023cites this paper
• Detecting and Quantifying pADPr In Vivo.

  2023cites this paper
• Copper-Mediated Radiobromination of (Hetero)Aryl Boronic Pinacol Esters.

  2023cites this paper
• Isolation and detection of DNA–protein crosslinks in mammalian cells

  2023cites this paper
• Dual antitumor immunomodulatory effects of PARP inhibitor on the tumor microenvironment: A counterbalance between anti-tumor and pro-tumor.

  2023cites this paper
• SETD2 Deficiency Confers Sensitivity to Dual Inhibition of DNA Methylation and PARP in Kidney Cancer.

  2023cites this paper
• Small cell lung cancer: novel treatments beyond immunotherapy.

  2022cites this paper
• Talazoparib, a Poly(ADP-ribose) Polymerase Inhibitor, for Metastatic Castration-resistant Prostate Cancer and DNA Damage Response Alterations: TALAPRO-1 Safety Analyses

  2022influential citation
• Pharmacokinetics and Pharmacodynamics of PARP Inhibitors in Oncology

  2022cites this paper
• Sex steroid hormones and DNA repair regulation: implications on cancer treatment responses.

  2022cites this paper
• A comprehensive comparison of medication strategies for platinum-sensitive recurrent ovarian cancer: A Bayesian network meta-analysis

  2022cites this paper
• Pelargonidin ameliorates reserpine-induced neuronal mitochondrial dysfunction and apoptotic cascade: a comparative in vivo study

  2022cites this paper
• Recent advances in structural types and medicinal chemistry of PARP-1 inhibitors

  2022cites this paper
• Why medicines work.

  2022cites this paper
• Targeting cancer stem cells in the tumor microenvironment: An emerging role of PARP inhibitors.

  2022cites this paper
• PARP inhibitor BMN-673 induced apoptosis by trapping PARP-1 and inhibiting base excision repair via modulation of Pol-β in chromatin of breast cancer cells.

  2022cites this paper
• Recent advances in phenotypic drug discovery [version 1; peer review: 2 approved]

  2022cites this paper
• Revisiting PARP2 and PARP1 trapping through quantitative live-cell imaging.

  2022cites this paper
• Therapeutic implications of germline vulnerabilities in DNA repair for precision oncology.

  2022cites this paper
• Triple negative breast cancer: approved treatment options and their mechanisms of action

  2022cites this paper
• Targeting PARP proteins in acute leukemia: DNA damage response inhibition and therapeutic strategies

  2022cites this paper
• Efficacy of Clinically Used PARP Inhibitors in a Murine Model of Acute Lung Injury

  2022cites this paper
• Novel LC–MS Method development and Validation for Characterization of Talazoparib, an Anti-cancer drug and its forced degradation behavior

  2022cites this paper
• Preclinical Assessment of the Combination of PSMA-Targeting Radionuclide Therapy with PARP Inhibitors for Prostate Cancer Treatment

  2022cites this paper
• BMN673 Is a PARP Inhibitor with Unique Radiosensitizing Properties: Mechanisms and Potential in Radiation Therapy

  2022cites this paper
• The Important Role of Poly ADP-Ribose Polymerase Inhibitor in Prostate Cancer

  2022cites this paper
• Homologous Recombination Deficiency Scar: Mutations and Beyond—Implications for Precision Oncology

  2022cites this paper
• Targeting Replication Stress Response Pathways to Enhance Genotoxic Chemo- and Radiotherapy

  2022cites this paper
• Role of PARP Inhibitors in Cancer Immunotherapy: Potential Friends to Immune Activating Molecules and Foes to Immune Checkpoints

  2022cites this paper
• Human PARP1 Facilitates Transcription through a Nucleosome and Histone Displacement by Pol II In Vitro

  2022cites this paper
• Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial.

  2021cites this paper
• The Role of ARID1A in Tumors: Tumor Initiation or Tumor Suppression?

  2021cites this paper
• Dual PARP and RAD51 Inhibitory Drug Conjugates Show Synergistic and Selective Effects on Breast Cancer Cells

  2021influential citation
• Selective therapeutic strategy for p53-deficient cancer by targeting dysregulation in DNA repair

  2021cites this paper
• Cell-cycle-dependent EBNA1-DNA crosslinking promotes replication termination at oriP and viral episome maintenance.

  2021cites this paper
• Development of the PARP inhibitor talazoparib for the treatment of advanced BRCA1 and BRCA2 mutated breast cancer

  2021cites this paper
• Olaparib combined with chemotherapy for treatment of T-cell acute lymphoblastic leukemia relapse after unrelated umbilical cord blood transplantation

  2021cites this paper
• Safety, pharmacokinetics, and preliminary efficacy of the PARP inhibitor talazoparib in Japanese patients with advanced solid tumors: phase 1 study

  2021cites this paper
• PARP Inhibitors Talazoparib and Niraparib Sensitize Melanoma Cells to Ionizing Radiation

  2021cites this paper
• Selective therapeutic strategy for p53-deficient cancer by targeting dysregulation in DNA repair

  2021cites this paper
• Discovery of pyrano[2,3-d]pyrimidine-2,4-dione derivatives as novel PARP-1 inhibitors: design, synthesis and antitumor activity

  2021cites this paper
• Genomic Instability and DNA Repair in Cancer

  2021cites this paper
• Synthesis and evaluation of 2‐(4‐[4‐acetylpiperazine‐1‐carbonyl] phenyl)‐1H‐benzo[d]imidazole‐4‐carboxamide derivatives as potential PARP‐1 inhibitors and preliminary study on structure‐activity relationship

  2021cites this paper
• Safety, Pharmacokinetics, and Preliminary E�cacy of Talazoparib in Japanese Patients With Advanced Solid Tumors: Phase 1 Study Phase Study

  2021cites this paper
• PARP Inhibitors in Pancreatic Cancer

  2021cites this paper
• PARP inhibitors and the Kidney

  2021cites this paper
• A subset of PARP inhibitors induces lethal telomere fusion in ALT-dependent tumor cells

  2021cites this paper
• Evaluation of Poly(ADP-ribose) Polymerase Inhibitor, Pamiparib (BGB-290) in Treating Acute Myeloid Leukemia and the Characterization of Its Nanocarrier.

  2021cites this paper
• Epigenetic Treatment of Urothelial Carcinoma Cells Sensitizes to Cisplatin Chemotherapy and PARP Inhibitor Treatment

  2021cites this paper
• PARP1: Structural insights and pharmacological targets for inhibition.

  2021cites this paper
• PARP Inhibition in Advanced Prostate Cancer

  2021cites this paper
• Comprehensive Analysis of Genome-instability Related lncRNAs and Tumor-immune Microenvironment to Discriminate the Prognosis, Immunotherapy and PARP Inhibitor Responses in Patients with Low-grade Glioma

  2021cites this paper
• Pelargonidin as an Attenuator of Neuronal Mitochondrial Dysfunction: An in Vivo Study

  2021cites this paper
• Rucaparib in patients with BAP1-deficient or BRCA1-deficient mesothelioma (MiST1): an open-label, single-arm, phase 2a clinical trial.

  2021cites this paper